anti-Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Antibodies

The protein encoded by TNFRSF8 is a member of the TNF-receptor superfamily. Additionally we are shipping TNFRSF8 Kits (68) and TNFRSF8 Proteins (31) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
TNFRSF8 943 P28908
TNFRSF8 21941 Q60846
TNFRSF8 25069 P97525
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-TNFRSF8 Antibodies at antibodies-online.com

Showing 10 out of 498 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Human Mouse Un-conjugated IHC, IHC (p), WB 100 μL 11 to 14 Days
$522.50
Details
Human Rabbit Un-conjugated WB Anti-CD30 Picoband antibody, All lanes: Anti-CD30 at 0.5ug/ml Lane 1: HELA Whole Cell Lysate at 40ug Lane 2: 293T Whole Cell Lysate at 40ug Lane 3: JURKAT Whole Cell Lysate at 40ugPredicted bind size: 67KDObserved bind size: 67KD 100 μg 4 to 6 Days
$240.00
Details
Human Mouse Un-conjugated FACS, IHC (p), IP, WB 0.1 mg 6 to 8 Days
$346.50
Details
Human Mouse Un-conjugated FACS, IHC (p) Human Thymus (formalin-fixed, paraffin-embedded) stained with TNFRSF8 antibody LS-B1865 at 5 ug/ml followed by biotinylated anti-mouse IgG secondary antibody LS-D2, alkaline phosphatase-streptavidin and chromogen. 0.1 mg 5 to 7 Days
$360.22
Details
Human Mouse PE FACS, IHC (p) Surface staining of human blood cells with anti-CD30 (MEM-268) PE. 100 Tests 5 to 7 Days
$497.45
Details
Mouse Hamster FITC FACS 0.5 mg 6 to 8 Days
$456.50
Details
Human Mouse Un-conjugated WB 100 μL 11 to 14 Days
$522.50
Details
Human Mouse FITC FACS 50 μg 6 to 8 Days
$346.50
Details
Human Mouse Un-conjugated ELISA, FACS, WB Black line: Control Antigen (100 ng);Purple line: Antigen(10ng);Blue line: Antigen (50 ng);Red line: Antigen (100 ng); Dilution: 1/10000 Figure 1: Western blot analysis using CD30 mAb against human CD30 (AA: 536-590) recombinant protein. (Expected MW is 32 kDa)  Dilution: 1/500 - 1/2000 100 μL 8 to 11 Days
$577.50
Details
Human Mouse Un-conjugated FACS, IHC, IHC (p) Anti-TNFRSF8 / CD30 antibody IHC staining of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody  ABIN1104732 concentration 5 ug/ml. Anti-TNFRSF8 / CD30 antibody IHC of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. 0.05 mg 11 to 14 Days
$484.00
Details

Top referenced anti-TNFRSF8 Antibodies

  1. Mouse (Murine) Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN2689176 : Amakawa, Hakem, Kundig, Matsuyama, Simard, Timms, Wakeham, Mittruecker, Griesser, Takimoto, Schmits, Shahinian, Ohashi, Penninger, Mak: Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. in Cell 1996 (PubMed)
    Show all 12 Pubmed References

  2. Human Monoclonal TNFRSF8 Primary Antibody for IHC (f), FACS - ABIN2749181 : Aalberse, Kapitein, de Roock, Klein, de Jager, van der Zee, Hoekstra, van Wijk, Prakken: Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60). in PLoS ONE 2011 (PubMed)
    Show all 5 Pubmed References

  3. Human Monoclonal TNFRSF8 Primary Antibody for IHC (f), FACS - ABIN2749180 : Franke, Jung, Ellis: Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. in Hybridoma 2000 (PubMed)
    Show all 5 Pubmed References

  4. Human Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN536665 : Wright, Rumble, Duckett: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. in The Journal of biological chemistry 2007 (PubMed)
    Show all 3 Pubmed References

  5. Human Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN536664 : Zeiser, Nguyen, Hou, Beilhack, Zambricki, Buess, Contag, Negrin: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. in Blood 2007 (PubMed)
    Show all 3 Pubmed References

  6. Human Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN536663 : Kusanovic, Romero, Hassan, Gotsch, Edwin, Chaiworapongsa, Erez, Mittal, Mazaki-Tovi, Soto, Than, Friel, Yoon, Espinoza: Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. in The journal of maternal-fetal & neonatal medicine 2008 (PubMed)
    Show all 3 Pubmed References

  7. Human Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN610027 : Dayanir, Meyer, Lashkari, Rahimi: Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. in The Journal of biological chemistry 2001 (PubMed)
    Show all 2 Pubmed References

  8. Human Monoclonal TNFRSF8 Primary Antibody for Agon, CyTOF - ABIN5012858 : Schwertassek, Balmer, Gutscher, Weingarten, Preuss, Engelhard, Winkler, Dick: Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. in The EMBO journal 2007 (PubMed)
    Show all 2 Pubmed References

  9. Human Monoclonal TNFRSF8 Primary Antibody for FACS, IHC (p) - ABIN192353 : Pavlov, Martins, Delgado: Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. in Clinical and vaccine immunology : CVI 2009 (PubMed)
    Show all 7 Pubmed References

  10. Human Monoclonal TNFRSF8 Primary Antibody for FACS, IHC (p) - ABIN192354 : Polte, Behrendt, Hansen: Direct evidence for a critical role of CD30 in the development of allergic asthma. in The Journal of allergy and clinical immunology 2006 (PubMed)
    Show all 7 Pubmed References

More Antibodies against TNFRSF8 Interaction Partners

Human Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) interaction partners

  1. Review of 585 cases found strong and uniform positive CD30 staining in Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma as well as variable CD30 staining in non-Hodgkin lymphomas. In addition, CD30 staining was found in some cases of neuroblastoma (particularly in cells with ganglion differentiation), myeloid neoplasms, neoplasm with chondrocytic differentiation, and hemangiomas.

  2. CD30 and CD30L were involved in pulmonary vascular remodeling and inflammatory response in COPD.

  3. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression.

  4. Data suggest that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut-associated lymphoid tissue.

  5. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers.

  6. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

  7. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma.

  8. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs).

  9. median FoxP3+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0

  10. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

  11. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

  12. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized.

  13. Higher serum sCD30 levels were associated with an increased risk of bacterial infection after kidney transplantation.

  14. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients.

  15. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90.

  16. this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients

  17. CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL.

  18. Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma.

  19. The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells.

  20. CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) interaction partners

  1. This study demonstrated the amelioration of MOG35-55 peptide-induced active EAE in CD30 KO mice. CD30 was expressed limitedly on CD4 T cells at the induction phase of experimental autoimmune encephalomyelitis.

  2. Data indicate that CD30L/CD30 axis plays a modulatory role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE).

  3. role in the maintenance and activation of IL-17A-producing gammadelta T cells

  4. These results suggest that CD30 signaling plays an important role in the activation of IL-17A-producing Vgamma1(-) Vgamma4(-) gammadelta T cells bearing Vgamma6 at an early stage of BCG infection.

  5. Interference of the CD30-CD30L pathway reduces atherosclerosis development.

  6. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model

  7. role of CD30L/CD30 interactions in allergic rhinitis; results suggest that CD30L plays an important role in allergic rhinitis

  8. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice.

  9. Studies demonstrate that CD30L/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation.

  10. CD30 can signal in a completely TCR-independent fashion to induce IL-13 production by effector T cells.

  11. Immunity to CD30 could play a role in Marek disease lymphoma regression.

  12. Deficiencies in OX40 and CD30 signals were additive, secondary Ab responses were ablated.OX40/CD30 double-knockout OTII transgenic T cells fail to survive compared with normal T cells when cocultured with CD4(+)CD3(-) cells in vitro.

  13. CD30 plays an important role in the generation of long-lived memory CD8+ T cells, at least partly by triggering homing receptors for T(central memory) cells.

  14. early CD30 signaling is critical for regulatory T cells-mediated acute graft-versus-host disease protection after major MHC-mismatch bone marrow transplantation

  15. These results indicate that CD30 is a regulator of T(h)2 responses in the effector-memory phase and a regulator of IL-13 production in memory cells in the lung.

  16. CD30L/CD30 signaling is involved in development of both OXA- and TNBS-induced colitis. Modulation of CD30L/CD30 signaling by mAb could be a novel biologic therapy for inflammatory bowel diseases.

  17. CD30 and OX40 signals are both required for the survival but not commitment of CD4 T helper type 1 (Th1) cells.

  18. Signaling executed by CD30positive T cell interaction with CD30Lpositive T cells plays a critical role in amplification of T helper type (Th)1 responses that able to produce interferon-gamma against Mycobacterium bovis bacillus Calmette-Guerin infection.

  19. ko mice exhibite delayed structuring of pulmonary granulomas and reduced recruitment of lymphocytes after infection with erogenic Mycobacterium avium

  20. CD30 signals from lymphoid tissue inducer cells were a primitive mechanism to recruit and prime CD4 T cells

TNFRSF8 Antigen Profile

Protein Summary

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Gene names and symbols associated with TNFRSF8

  • TNF receptor superfamily member 8 (TNFRSF8) antibody
  • tumor necrosis factor receptor superfamily, member 8 (Tnfrsf8) antibody
  • TNF receptor superfamily member 8 (Tnfrsf8) antibody
  • Cd30 antibody
  • D1S166E antibody
  • Ki antibody
  • Ki-1 antibody
  • TNFRSF8 antibody

Protein level used designations for TNFRSF8

CD30L receptor , Ki-1 antigen , cytokine receptor CD30 , lymphocyte activation antigen CD30 , tumor necrosis factor receptor superfamily member 8 , Tumor necrosis factor superfamily member 8 , tumor necrosis factor superfamily, member CD30 , tumor necrosis factor receptor superfamily, member 8 , tumor necrosis factor receptor superfamily member 8-like

GENE ID SPECIES
943 Homo sapiens
21941 Mus musculus
25069 Rattus norvegicus
395090 Gallus gallus
457960 Pan troglodytes
487438 Canis lupus familiaris
614780 Bos taurus
722773 Macaca mulatta
100385465 Callithrix jacchus
100579424 Nomascus leucogenys
Selected quality suppliers for anti-TNFRSF8 (TNFRSF8) Antibodies
Did you look for something else?